Ozempic Dosing and Safety Considerations

Special Population Considerations

No dosage adjustment is required for patients with renal impairment, including those with end-stage renal disease, as recommended by the Endocrine Society and Kidney International 1, 2
No dosage adjustment is required for patients with hepatic impairment, as recommended by Kidney International 2

The gradual dose titration schedule helps minimize gastrointestinal adverse effects, as reported by medical insights 3
Monitor for potential consequences of delayed absorption of oral medications with narrow therapeutic indices, as advised by the American Diabetes Association in Diabetes Care 4
Use caution when combining with insulin or insulin secretagogues due to potential hypoglycemia risk; dose adjustments of these medications may be needed, as recommended by the American Diabetes Association in Diabetes Care 4

Semaglutide carries a black box warning regarding the risk of thyroid C-cell tumors in rodents (human relevance not determined); do not use in individuals with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, as warned by the American Diabetes Association in Diabetes Care 4
May cause cholelithiasis and gallstone-related complications, as reported by the American Diabetes Association in Diabetes Care 4
May cause gastrointestinal disorders including severe constipation and small bowel obstruction/ileus progression, as reported by the American Diabetes Association in Diabetes Care 4
May cause elevated heart rate, as reported by the American Diabetes Association in Diabetes Care 4